🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

65,67 USD

Máx. histórico

89,55

119 días

Caída desde máximo

-26,67%

Rango 52 semanas

58,80 – 90,87

Variación hoy

-4,79%

Cierre anterior

68,97

Rango de hoy

65,45 – 69,59

Volumen hoy

1.228.468

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 2 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/02/2019 30,85 31,37 30,58 30,71 -0,68% 2,56% 465.800
01/02/2019 31,13 31,66 30,62 30,92 -0,67% 3,34% 1.127.300
31/01/2019 29,67 31,71 29,59 31,13 +4,08% 7,15% 1.256.900
30/01/2019 28,84 30,03 28,72 29,91 +6,25% 4,54% 1.294.600
29/01/2019 28,27 28,39 27,55 28,15 +0,21% 2,97% 586.000
28/01/2019 28,86 29,28 27,53 28,09 -4,52% 6,06% 1.465.800
25/01/2019 29,75 29,86 28,80 29,42 -0,10% 3,58% 1.507.200
24/01/2019 29,90 29,90 29,28 29,45 -0,64% 2,07% 982.800
23/01/2019 30,22 30,35 29,15 29,64 -10,24% 3,97% 5.265.600
22/01/2019 34,07 34,07 32,83 33,02 -4,12% 3,64% 739.500
18/01/2019 34,75 35,00 33,81 34,44 -0,49% 3,42% 546.400
17/01/2019 34,62 35,18 34,30 34,61 -0,75% 2,54% 430.300
16/01/2019 35,02 36,00 34,73 34,87 -0,23% 3,63% 488.000
15/01/2019 34,99 35,25 34,45 34,95 +0,37% 2,27% 448.300
14/01/2019 35,48 35,82 34,69 34,82 -2,46% 3,18% 593.200
11/01/2019 37,77 37,77 35,58 35,70 -5,95% 5,80% 462.000
10/01/2019 37,43 38,61 36,40 37,96 +1,20% 5,90% 820.900
09/01/2019 36,39 38,98 35,24 37,51 +3,08% 10,28% 922.800
08/01/2019 35,83 36,61 34,05 36,39 +2,02% 7,14% 1.151.300
07/01/2019 34,81 36,01 33,91 35,67 -0,53% 6,03% 1.241.500
04/01/2019 33,80 35,98 32,20 35,86 +7,27% 11,18% 985.100
03/01/2019 33,56 34,14 32,61 33,43 -0,54% 4,56% 658.100
02/01/2019 33,60 34,14 32,96 33,61 -2,07% 3,51% 629.500
31/12/2018 32,50 34,57 32,50 34,32 +7,22% 6,37% 896.000
28/12/2018 31,96 33,07 31,31 32,01 +0,22% 5,51% 569.400
27/12/2018 32,32 32,34 30,27 31,94 -3,12% 6,40% 698.100
26/12/2018 30,14 33,05 30,10 32,97 +10,53% 9,79% 637.400
24/12/2018 29,74 30,54 28,91 29,83 -1,32% 5,48% 249.500
21/12/2018 31,21 32,14 29,00 30,23 -2,48% 10,07% 1.614.400
20/12/2018 31,91 33,00 30,29 31,00 -3,13% 8,48% 787.700